Canada makes history as the first G7 nation to approve generic, Health Canada says
Just 2.1% of claimants now drive more than one‑third of private drug‑plan costs
Eli Lilly commits up to US$2.3 billion to test a new option for resistant myelofibrosis patients
One Medical’s new GLP-1 programme could reset access and cost expectations for Canadian plan sponsors
